For patients in the very early stages of mild cognitive impairment, prognosis can be gauged with PET imaging using two different tracers — fluorodeoxyglucose (FDG) and florbetapir, which measures beta-amyloid pathology — according to new research reported here at the Society of Nuclear Medicine and Molecular Imaging 2015 Annual Meeting. {read more here}